Retraction notice to "Differential impact of diabetes and hypertension in the brain: Adverse effects in white matter" [Neurobiol. Dis., 42 (2011) 446-458, http://dx.doi.org/10.1016/j.nbd.2011.02.007];Differential impact of diabetes and hypertension in the brain: Adverse effects in white matter

Neurobiology of Disease

Volumn 42, Issue 3, 2011, Pages 446-458

  Yang, Christina ^a   DeVisser, Adriena ^a   Martinez, Jose A ^a   Poliakov, Ilia ^a   Rosales Hernandez, Alma ^a   Ayer, Amit ^a   Garven, Alexandra ^a   Zaver, Shaila ^a   Rincon, Natalia ^a   Xu, Kevin ^a   Tuor, Ursula I ^a,b   Schmidt, Ann Marie ^c   Toth, Cory ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE   (United States)

Author keywords

Diabetes; Hypertension; Receptor for advanced glycation end products; Vascular disease; White matter abnormalities

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELIN; MYELIN PROTEIN;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DISEASE; BRAIN TISSUE; CONTROLLED STUDY; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WHITE MATTER ABNORMALITY;

EID: 79954630745     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.05.005     Document Type: Erratum

References (41)

1. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 2004, 25:5-18.
2. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., Hong M., Luther T., Henle T., Klöting I., Morcos M., Hofmann M., Tritschler H., Weigle B., Kasper M., Smith M., Perry G., Schmidt A.M., Stern D.M., Häring H.U., Schleicher E., Nawroth P.P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50:2792-2808.
3. Biessels G.J., Deary I.J., Ryan C.M. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008, 7:184-190.
4. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 2000, 21:153-160.
5. Brun A., Englund E. A white matter disorder in dementia of the alzheimer type: a pathoanatomical study. Ann. Neurol. 1986, 19:253-258.
6. Chaves C.J., Silver B., Schlaug G., Dashe J., Caplan L.R., Warach S. Diffusion- and perfusion-weighted MRI patterns in borderzone infarcts. Stroke 2000, 31:1090-1096.
7. Dahlquist G., Kallen B. School performance in children with type 1 diabetes-a population-based register study. Diabetologia 2007, 50:957-964.
8. de Groot J.C., de Leeuw F.E., Oudkerk M., van G.J., Hofman A., Jolles J., Breteler M.M. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann. Neurol. 2000, 47:145-151.
9. de Leeuw F.E., de Groot J.C., Achten E., Oudkerk M., Ramos L.M., Heijboer R., Hofman A., Jolles J., van Gijn J., Breteler M.M. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J. Neurol. Neurosurg. Psychiatry 2001, 70(1):9-14.
10. de Leeuw F.E., de Groot J.C., Oudkerk M., Witteman J.C., Hofman A., van Gijn J., Breteler M.M. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002, 125:765-772.
11. de Leeuw F.E., Barkhof F., Scheltens P. Alzheimer's disease-one clinical syndrome, two radiological expressions: a study on blood pressure. J. Neurol. Neurosurg. Psychiatry 2004, 75:1270-1274.
12. Jacobson A.M., Musen G., Ryan C.M., Silvers N., Cleary P., Waberski B., Burwood A., Weinger K., Bayless M., Dahms W., Harth J. Long-term effect of diabetes and its treatment on cognitive function. N. Engl. J. Med. 2007, 356:1842-1852. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group.
13. Dufouil C., de Kersaint-Gilly A., Besancon V., Levy C., Auffray E., Brunnereau L., Alperovitch A., Tzourio C. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology 2001, 56:921-926.
14. Francis G.J., Martinez J.A., Liu W.Q., Xu K., Ayer A., Fine J., Tuor U.I., Glazner G., Hanson L.R., Frey W.F., Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type 1 diabetic encephalopathy. Brain 2008, 131:3311-3334.
15. Gao L., Matthews F.E., Sargeant L.A., Brayne C., MRC CFAS An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health 2008, 8:54.
16. Henning E.C., Warach S., Spatz M. Hypertension-induced vascular remodeling contributes to reduced cerebral perfusion and the development of spontaneous stroke in aged SHRSP rats. J. Cereb. Blood Flow Metab. 2010, 30:827-836.
17. Jacobson A.M., Musen G., Ryan C.M., Silvers N., Cleary P., Waberski B., Burwood A., Weinger K., Bayless M., Dahms W., Harth J. Long-term effect of diabetes and its treatment on cognitive function. N. Engl. J. Med. 2007, 356:1842-1852.
18. Kamal A., Biessels G.J., Gispen W.H., Ramakers G.M. Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Res. 2006, 1073-1074:276-280.
19. Knopman D., Boland L.L., Mosley T., Howard G., Liao D., Szklo M., McGovern P., Folsom A.R. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42-48. Atherosclerosis Risk in Communities (ARIC) Study Investigators.
20. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
21. Lipscombe L.L., Hux J.E. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007, 369:750-756.
22. Meneses A., Castillo C., Ibarra M., Hong E. Effects of aging and hypertension on learning, memory, and activity in rats. Physiol. Behav. 1996, 60:341-345.
23. Qiao M., Latta P., Foniok T., Buist R., Meng S., Tomanek B., Tuor U.I. Cerebral blood flow response to a hypoxic-ischemic insult differs in neonatal and juvenile rats. Magma 2004, 17:117-124.
24. Rafikova O., Salah E.M., Tofovic S.P. Renal and metabolic effects of tempol in obese ZSF1 rats-distinct role for superoxide and hydrogen peroxide in diabetic renal injury. Metabolism 2008, 57:1434-1444.
25. Rosano C., Sigurdsson S., Siggeirsdottir K., Phillips C.L., Garcia M., Jonsson P.V., Eiriksdottir G., Newman A.B., Harris T.B., van Buchem M.A., Gudnason V., Launer L.J. Magnetization transfer imaging, white matter hyperintensities, brain atrophy and slower gait in older men and women. Neurobiol. Aging 2010, 31:1197-1204.
26. Ryan C.M., Williams T.M. Effects of insulin-dependent diabetes on learning and memory efficiency in adults. J. Clin. Exp. Neuropsychol. 1993, 15:685-700.
27. Ryan C.M., Williams T.M., Finegold D.N., Orchard T.J. Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 1993, 36:329-334.
28. Sabbatini M., Catalani A., Consoli C., Marletta N., Tomassoni D., Avola R. The hippocampus in spontaneously hypertensive rats: an animal model of vascular dementia?. Mech. Ageing Dev. 2002, 123:547-559.
29. Scartozzi M., Bearzi I., Pierantoni C., Mandolesi A., Loupakis F., Zaniboni A., Catalano V., Quadri A., Zorzi F., Berardi R., Biscotti T., Labianca R., Falcone A., Cascinu S. Nuclear factor-kB expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan Therapy. J. Clin. Oncol. 2007, 25:3930-3935.
30. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 1995, 96:1395-1403.
31. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 1999, 84:489-497.
32. Schmidt R., Fazekas F., Offenbacher H., Dusek T., Zach E., Reinhart B., Grieshofer P., Freidl W., Eber B., Schumacher M. Neuropsychologic correlates of MRI white matter hyperintensities: a study of 150 normal volunteers. Neurology 1993, 43:2490-2494.
33. Schoenle E.J., Schoenle D., Molinari L., Largo R.H. Impaired intellectual development in children with Type 1 diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia 2002, 45:108-114.
34. Sjobeck M., Englund E. Glial levels determine severity of white matter disease in Alzheimer's disease: a neuropathological study of glial changes. Neuropathol. Appl. Neurobiol. 2003, 29:159-169.
35. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
36. Tan L., Schedl P., Song H.J., Garza D., Konsolaki M. The Toll->NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer's Abeta42 polypeptide in Drosophila. PLoS ONE 2008, 3:e3966.
37. Toth C., Schmidt A.M., Tuor U.I., Francis G., Foniok T., Brussee V., Kaur J., Yan S.F., Martinez J.A., Barber P.A., Buchan A., Zochodne D.W. Diabetes, leukoencephalopathy and RAGE. Neurobiol. Dis. 2006, 23:445-461.
38. Vermeer S.E., Hollander M., van Dijk E.J., Hofman A., Koudstaal P.J., Breteler M.M. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003, 34:1126-1129.
39. Wautier J.L., Guillausseau P.J. Advanced glycation end products, their receptors and diabetic angiopathy. Diab. Metab. 2001, 27:535-542.
40. Wuerfel J., Bellmann-Strobl J., Brunecker P., Aktas O., McFarland H., Villringer A., Zipp F. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004, 127:111-119.
41. Yan S.D., Schmidt A.M., Anderson G.M., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 1994, 269:9889-9897.